Skip to main content
Elliot Servais, MD, Thoracic Surgery, Burlington, MA

ElliotLouisServaisMDFACS

Thoracic Surgery Burlington, MA

Adult General Thoracic Surgery, Minimally Invasive Thoracic Surgery, Thoracic Surgical Oncology, Cardiovascular Surgery

Vice Chair, Department of Surgery; Director of Robotic Thoracic Surgery

Dr. Servais is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Servais' full profile

Already have an account?

  • Office

    41 Mall Rd
    Burlington, MA 01805
    Phone+1 781-744-8570
    Fax+1 781-744-5641

Summary

  • Dr. Servais is a board-certified general thoracic surgeon with expertise in diseases of the chest and abdomen. He has particular interest in thoracic oncology (including cancers of the lungs, esophagus, mediastinum, pleura, and chest wall) and esophageal motility disorders (gastroesophageal reflux, paraesophageal/hiatal hernia, and achalasia).

    Dr. Servais uses minimally-invasive surgical techniques such as laparoscopy, thoracoscopy or VATS, and has expertise in robotic surgery to minimize pain and post-operative recovery time, while optimizing oncologic and functional outcomes.

    Dr. Servais is one of the highest volume robotic thoracic surgeons in the region performing operations such as robotic lobectomy for lung cancer and robotic minimally invasive esophagectomy for esophageal cancer.

    Dr. Servais also has expertise in advanced endoscopic and bronchoscopic techniques such as endobronchial ultrasound (EBUS) and per-oral endoscopic myotomy (POEM) for achalasia.

    Dr. Servais' research interests include:
    -Biomarker discovery and evaluation for early detection and therapeutic response in lung and esophageal cancer
    -Evaluation of targeted therapies in thoracic malignancies
    -Clinical outcomes research in thoracic surgery

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Thoracic Surgery, 2013 - 2015
  • Brigham and Women's Hospital/Children's Hospital
    Brigham and Women's Hospital/Children's HospitalFellowship, Thoracic Surgery, 2013 - 2015
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 2006 - 2013
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Thoracic Surgical Oncology, 2008 - 2010
  • Boston University School of Medicine
    Boston University School of MedicineClass of 2006
  • Boston University
    Boston UniversityBA, Medical Program, Summa Cum Laude, 2003

Certifications & Licensure

  • NH State Medical License
    NH State Medical License 2015 - Present
  • MA State Medical License
    MA State Medical License 2013 - 2026
  • NY State Medical License
    NY State Medical License 2007 - 2014
  • American Board of Surgery Surgery
  • American Board of Thoracic Surgery Thoracic and Cardiac Surgery

Awards, Honors, & Recognition

  • John J. Collins Jr., M.D. Award Brigham and Women’s Hospital, Harvard Medical School, 2015
  • Distinguished Housestaff Award NewYork-Presbyterian Hospital Alumni Council, Weill Cornell Medical College, 2012
  • Finalist 15th Annual C. Walton Lillehei Resident Research Forum, 92nd Annual AATS Meeting, 2012
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Thoracoscopic management of pulmonary metastases  
    Servais EL. Swanson SJ., Thoracic Surgery Clinics, 1/1/2016
  • Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma  
    Kachala SS. Bograd AJ. Villena-Vargas J. Suzuki K. Servais EL. Kadota K. Chou J. Sima CS. Vertes E. Rusch VW. Travis WD. Sadelain M. Adusumilli PS., Clinical Cancer Research, 1/1/2014
  • Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity  
    Adusumilli PS. Cherkassky L. Villena-Vargas J. Colovos C. Servais E. Plotkin J. Jones DR. Sadelain M., Science Translational Medicine, 1/1/2014
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Pre-operative Consolidation to Tumor Ratio on Computed Tomography and FDG-PET SUVmax Predict Recurrence after Limited Resection of Early Lung Adenocarcinoma
    Servais EL. Nitadori J. Morales EA. Suzuki K. Bograd AJ. Rizk NP. Downey RJ. Rusch VW. Adusumilli PS., American Association for Thoracic Surgery (AATS), San Francisco, CA, 1/1/2012
  • A preclinical mouse model of orthotopic pleural cancer that facilitates noninvasive quantitative monitoring of tumor progression and therapy response
    Servais EL. Velez MC. Rusch VW. Sadelain M. Adusumilli PS., Cancer Res, AACR Frontiers in Basic Cancer Research Meeting, 1/1/2009
  • Intra-operative Pulse Oximetry
    Oliveira L, Servais E, Rizk N, Adusumilli P, Bikson M., Journal of Medical Devices, 1/1/2009
  • Join now to see all

Lectures

  • Mesothelin Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Malignant Pleural Mesothelioma (MPM) Patients: A Potential Mecha... 
    San Francisco, CA - 1/1/2012
  • Mesothelin decreases recurrence-free survival in lung adenocarcinoma by imparting an aggressive phenotype 
    Minneapolis, MN - 1/4./2013
  • Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM) 
    Washington, DC - 1/6./2010
  • Join now to see all

Press Mentions

  • #15: CTSNet Beat Podcast: World Society of Cardiovascular & Thoracic Surgeons
    #15: CTSNet Beat Podcast: World Society of Cardiovascular & Thoracic SurgeonsMay 11th, 2021

Professional Memberships